Traders floated scenarios ranging from a $20 billion buyout to a potential partnership with UnitedHealth, reviving Viking’s ...

Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug. Eli Lilly and Novo Nordisk have ...

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's revenue rose 14% -- less than traditional cruise line companies -- but there are ...

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking could ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

Detailed price information for Viking Holdings Ltd (VIK-N) from The Globe and Mail including charting and trades.

JP Morgan analyst Matthew Boss reiterated an Overweight rating on the shares of Viking Holdings Ltd (NYSE:VIK) and raised the price target to $58 from $50. From 2017 to 2019, VIK’s pre-pandemic annual ...

Viking Holdings Ltd continues to outperform, driven by strong baby boomer demand, double-digit revenue growth. Learn more ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...

Viking Global Investors LP, managed by Andreas Halvorsen, recently executed a significant transaction involving Nvidia ...